natgillin/translations-raw huggingface dataset:
Patients were randomised to receive either FOLFIRI plus bevacizumab (Arm-A, n=167) or XELIRI plus bevacizumab (Arm-B, n-166). 
Bolnike so randomizirali, da so prejeli FOLFIRI in bevacizumab (skupina A, n = 167) ali XELIRI in bevacizumab (skupina B, n = 166).
Your doctor may want you to take a combination of 150 mg, 300 mg and 500 mg tablets for each dose. 
Zdravnik vam bo morda predpisal jemanje kombinacije 150-mg, 300-mg in 500-mg tablet pri vsakem odmerku.
- first-line treatment of advanced gastric cancer in combination with a platinum based regimen (see section 5.1). 
- za prvo linijo zdravljenja napredovalega raka želodca v kombinaciji s shemo na osnovi platine (glejte poglavje 5.1).
However, similar to other nucleoside analogues (ie, 5-FU), capecitabine was clastogenic in human lymphocytes (in vitro) and a positive trend occurred in mouse bone marrow micronucleus tests (in vivo). 
Podobno kakor drugi nukleozidni analogi, kot je 5-FU, je bil kapecitabin v človeških limfocitih klastogen (in vitro), mikronukleozni test (in vivo) v celicah kostnega mozga miši pa je imel pozitivno tendenco.
The study contained two parts: an initial 2-arm part in which 634 patients were randomised to two different treatment groups, including XELOX or FOLFOX-4, and a subsequent 2x2 factorial part in which 1401 patients were randomised to four different treatment groups, including XELOX plus placebo, FOLFOX-4 plus placebo, XELOX plus bevacizumab, and FOLFOX-4 plus bevacizumab. 
Študija je bila sestavljena iz dveh delov: začetnega dela iz dveh skupin, v katerem so 634 bolnikov randomizirali v dve različni skupini zdravljenja, po shemi XELOX ali shemi FOLFOX-4, in poznejšega dela s faktorskim načrtom 2x2 v katerem so 1.401 bolnika randomizirali v štiri različne skupine zdravljenja, XELOX in placebo, FOLFOX-4 in placebo, XELOX in bevacizumab ter FOLFOX-4 in bevacizumab.
Two examples are provided here: A person whose body weight is 64 kg and height is 1.64 m has a body surface area of 1.7 m2 and should take 4 tablets of 500 mg and 1 tablet of 150 mg two times daily. 
Navedena sta dva primera: oseba, ki tehta 64 kg in je visoka 1,64 m, ima telesno površino 1,7 m2 in jemlje 4 tablete po 500 mg in 1 tableto po 150 mg dvakrat na dan.
These dose adjustment recommendations for renal impairment apply both to monotherapy and combination use (see also section "Elderly" below). 
Priporočila za prilagajanje odmerkov pri ledvični okvari veljajo za samostojno in kombinirano zdravljenje (glejte tudi spodnji odstavek Starejši bolniki).
Film-coating 
Filmska obloga
The overall objective response rates (investigator assessment) were 20% (first trial) and 25% (second trial). 
Celotni objektivni odziv po oceni raziskovalca je bil v prvem preskušanju 20-%, v drugem pa 25-%.
Advanced gastric cancer: 
Napredovali rak želodca:
Number of 150 mg tablets, 300 mg tablets and/or 500 mg tablets per administration (each administration to be given morning and evening) 
Število 150-mg tablet, 300-mg tablet in/ali 500-mg tablet za posamezno dajanje (zdravilo se daje zjutraj in zvečer)
Grade 4 diarrhoea is an increase of ≥10 stools/day or grossly bloody diarrhoea or the need for parenteral support. 
Driska stopnje 4 pomeni 10 ali več izpraznitev črevesa na dan ali močne krvave driske ali potrebo po parenteralni hidraciji.
Administration with food decreases the rate of capecitabine absorption, but only results in a minor effect on the AUC of 5'-DFUR, and on the AUC of the subsequent metabolite 5-FU. 
Jemanje s hrano zmanjša hitrost absorpcije kapecitabina, kar pa ima le neznaten vpliv na AUC 5'-DFUR in na AUC presnovka 5-FU.
All grades 
Vse stopnje
Following grade 3 hand-foot syndrome, subsequent doses of capecitabine should be decreased. 
Po pojavu 3. stopnje moramo nadaljnje odmerke kapecitabina zmanjšati.
If you have an unrecognised DPD deficiency and take Ecansya, you are at an increased risk of acute early-onset of severe forms of the side effects listed under section 4 Possible side effects. 
Če ne veste, da imate pomanjkanje DPD in vzamete zdravilo Ecansya, imate večje tveganje za nenaden, zgodnji pojav hudih oblik neželenih učinkov, navedenih v poglavju 4, Možni neželeni učinki.
In this trial, 627 patients with metastatic colorectal carcinoma who have received prior treatment with irinotecan in combination with a fluoropyrimidine regimen as first line therapy were randomised to treatment with XELOX or FOLFOX-4. 
V tem preskušanju je bilo 627 bolnikov z metastatskim kolorektalnim rakom, ki so prej prejeli zdravljenje z irinotekanom v kombinaciji s fluoropirimidini v prvi liniji zdravljenja, randomiziranih v zdravljenje po shemi XELOX ali FOLFOX-4.
Median survival was 392 days (capecitabine) vs. 391 days (Mayo regimen). 
Mediana preživetja je bila 392 dni (kapecitabin) v primerjavi s 391 dnevi (shema Mayo).
There is no data on Ecansya and impact on fertility. 
Podatkov o vplivu zdravila Ecansya na plodnost ni.
Rigors, Body temperature increased ** Based on the post-marketing experience, persistent or severe palmar-plantar erythrodysaesthesia syndrome can eventually lead to loss of fingerprints (see section 4.4.) 
** Na podlagi izkušenj po prihodu zdravila na trg lahko vztrajen ali hud sindrom palmarno-plantarne eritrodisestezije sčasoma privede do izgube prstnih odtisov (glejte poglavje 4.4).
Brivudine: a clinically significant interaction between brivudine and fluoropyrimidines (e.g. capecitabine, 5-fluorouracil, tegafur), resulting from the inhibition of dihydropyrimidine dehydrogenase by brivudine, has been described. 
Brivudin: Opisali so klinično pomembno medsebojno delovanje med brivudinom in fluoropirimidini (npr. kapecitabinom, 5-fluorouracilom in tegafurjem), ki je rezultat brivudinovega zaviranja dihidropirimidin dehidrogenaze.
According to immunohistochemical studies, thymidine phosphorylase appears to be in large part localised in tumour stromal cells. 
Imunohistokemične študije kažejo, da se timidin fosforilaza večinoma nahaja v tumorskih stromalnih celicah.
If the other medicinal product(s) have to be discontinued permanently, capecitabine treatment can be resumed when the requirements for restarting capecitabine are met. 
Če je treba zdravljenje z drugim zdravilom oz. drugimi zdravili dokončno prekiniti, se lahko zdravljenje s kapecitabinom nadaljuje, ko so izpolnjeni pogoji za nadaljevanje zdravljenja s kapecitabinom.
Dose modifications for toxicity when capecitabine is used continuously in combination with other medicinal products 
Prilagajanje odmerkov zaradi toksičnosti, kadar se kapecitabin uporablja neprekinjeno v kombinaciji z drugimi zdravili
Therefore, brivudine must not be administered concomitantly with capecitabine (see section 4.3 and 4.4). 
Brivudina zato ne smemo dajati sočasno s kapecitabinom (glejte poglavji 4.3 in 4.4).
Acute renal failure secondary to dehydration might be potentially fatal. 
Akutna ledvična odpoved, ki nastopi zaradi dehidracije, je lahko smrtna.
Based on the population pharmacokinetic analysis, which included patients with a wide range of ages (27 to 86 years) and included 234 (46%) patients greater or equal to 65, age has no influence on the pharmacokinetics of 5'-DFUR and 5-FU. 
Na osnovi podatkov populacijske farmakokinetične študije, ki je zajela bolnike z velikim razponom v letih (27 do 86 let) in 234 bolnikov (46 %), starih 65 let ali starejših, so ugotovili, da starost ne vpliva na farmakokinetiko 5'- DFUR in 5- FU.
The median time to progression was 140 days (capecitabine) vs. 144 days (Mayo regimen). 
Mediana časa do napredovanja bolezni je bila 140 dni (kapecitabin) v primerjavi s 144 dnevi (shema Mayo).
In lactating mice, considerable amounts of capecitabine and its metabolites were found in milk. 
Pri miših v laktaciji so v mleku našli precej kapecitabina in njegovih presnovkov.
The time to peak plasma concentrations (Tmax in hours) were 1.50, 2.00, 2.00, 2.00 and 3.34. 
Časi do dosega največje plazemske koncentracije (Tmax v urah) so bili 1,50; 2,00; 2,00; 2,00 in 3,34.
The ratio of 5-FU concentration in tumour to plasma was 21.4 (ranged from 3.9 to 59.9, n=8) whereas the ratio in healthy tissues to plasma was 8.9 (ranged from 3.0 to 25.8, n=8). 
Razmerje koncentracij 5-FU v tumorjih v primerjavi s plazmo je bilo 21,4 (območje 3,9 do 59,9, n = 8), razmerje med zdravimi tkivi in plazmo pa 8,9 (območje 3,0 do 25,8, n = 8).
If you forget to take Ecansya 
Če ste pozabili vzeti zdravilo Ecansya
Oxaliplatin: no clinically significant differences in exposure to capecitabine or its metabolites, free platinum or total platinum occurred when capecitabine was administered in combination with oxaliplatin or in combination with oxaliplatin and bevacizumab. 
Oksaliplatin: Klinično pomembnih razlik v izpostavljenosti kapecitabinu ali njegovim presnovkom, prosti platini ali celokupni platini, ni bilo, ko so kapecitabin dajali v kombinaciji z oksaliplatinom ali v kombinaciji z oksaliplatinom in bevacizumabom.
The 5 year OS rate was 78% for XELOX versus 74% for 5-FU/LV. 
Delež celokupnega petletnega preživetja je bil 78 % za shemo XELOX v primerjavi s 74 % za 5-FU/LV.
When capecitabine was used in combination with other medicinal products, elderly patients (≥65 years) experienced more grade 3 and grade 4 adverse drug reactions, including those leading to discontinuation, compared to younger patients. 
Kadar so kapecitabin uporabljali z drugimi zdravili, so imeli starejši bolniki (stari 65 let ali več) v primerjavi z mlajšimi več neželenih učinkov stopnje 3 in 4, vključno s tistimi, ki so povzročili ukinitev zdravila.
Injury, poisoning and procedural complications 
Poškodbe in zastrupitve ter zapleti pri posegih kontuzija
Based on genetic toxicity findings, male patients with female partners of reproductive potential should use effective contraception during treatment and for 3 months following the last dose of capecitabine. 
Na podlagi ugotovitev o genetski toksičnosti morajo bolniki, ki imajo partnerko v rodni dobi, med zdravljenjem in še 3 mesece po zadnjem odmerku kapecitabina uporabljati učinkovito kontracepcijo.
The sequential enzymatic biotransformation of capecitabine to 5-FU leads to higher concentrations within tumour tissues. 
Postopna encimska biotransformacija kapecitabina v 5-FU daje večje koncentracije v tumorskih tkivih.
The median time to progression was 93 and 98 days. 
Mediana časa do napredovanja bolezni je bila v prvem preskušanju 93, v drugem pa 98 dni.
A person whose body weight is 80 kg and height is 1.80 m has a body surface area of 2.00 m2 and should take 5 tablets of 500 mg two times daily. 
Oseba, ki tehta 80 kg in je visoka 1,80 m, ima telesno površino 2,00 m2 in jemlje 5 tablet po 500 mg dvakrat na dan.
In human cancer xenograft models capecitabine demonstrated a synergistic effect in combination with docetaxel, which may be related to the upregulation of thymidine phosphorylase by docetaxel. 
V ksenografskih modelih raka pri ljudeh je imel kapecitabin v kombinaciji z docetakselom sinergistični učinek, kar je lahko povezano z uravnavanjem timidin fosforilaze zaradi docetaksela.
According to a pharmacokinetic study in cancer patients with mild to moderate liver impairment due to liver metastases, the bioavailability of capecitabine and exposure to 5-FU may increase compared to patients with no liver impairment. 
Glede na farmakokinetično študijo pri bolnikih z rakom, ki imajo blago ali zmerno jetrno okvaro zaradi zasevkov v jetrih, je biološka uporabnost kapecitabina in izpostavljenost 5- FU lahko povečana v primerjavi z bolniki brez okvare.
In addition, during a 13-week study, atrophic and degenerative changes occurred in reproductive organs of male mice; however these effects were reversible after a drug-free period (see section 4.6). 
Pri mišjih samcih pa so se v 13-tedenski študiji pojavile atrofične in degenerative spremembe na reproduktivnih organih, ki so po prenehanju jemanja kapecitabina izginile (glejte poglavje 4.6).
5-Fluorouracil 400 mg/m intravenous bolus, followed by 600 mg/ 2 intravenous 22 hr 
5-fluorouracil 400 mg/m intravensko bolus, sledi 600 mg/m intravensko 22 h placebo ali bevacizumab
Based on a pharmacokinetic study in cancer patients with mild to severe renal impairment, there is no evidence for an effect of creatinine clearance on the pharmacokinetics of intact drug and 5-FU. 
Glede na farmakokinetično študijo pri bolnikih, ki imajo blago do hudo ledvično okvaro, ni dokazov za vpliv kreatininskega očistka na farmakokinetiko zdravila in 5- FU.
Standard antidiarrhoeal treatments (e.g. loperamide) may be used. 
Priporočljivo je standardno zdravljenje (npr. z loperamidom).
Table 5 lists ADRs associated with the use of capecitabine in combination with different chemotherapy regimens in multiple indications based on safety data from over 3000 patients. 
Preglednica 5 našteva neželene učinke, povezane z uporabo kapecitabina v kombinaciji z različnimi kemoterapijami pri več indikacijah, ki temeljijo na podatkih o varnosti, zbranih pri več kot 3.000
Film-coated tablet (tablet). 
filmsko obložena tableta (tableta)
Capecitabine is contraindicated in patients with severe renal impairment (creatinine clearance below 30 ml/min [Cockcroft and Gault] at baseline). 
Kapecitabin je kontraindiciran pri bolnikih s hudo ledvično okvaro (očistek kreatinina pod 30 ml/min (Cockcroft in Gault) na začetku zdravljenja).
If you take more Ecansya than you should, contact your doctor as soon as possible before taking the next dose. 
Če ste vzeli večji odmerek zdravila Ecansya, kot bi smeli Če ste vzeli večji odmerek zdravila Ecansya, kot bi smeli, se takoj posvetujte z zdravnikom, še preden boste zaužili naslednjega.
Ecansya contains capecitabine, which itself is not a cytostatic medicine. 
Zdravilo Ecansya vsebuje kapecitabin, ki sam nima citostatičnega učinka.
When capecitabine and cisplatin are used in combination, the use of vitamin B6 (pyridoxine) is not advised for symptomatic or secondary prophylactic treatment of hand-foot syndrome, because of published reports that it may decrease the efficacy of cisplatin. 
Kadar kapecitabin in cisplatin uporabljamo v kombinaciji, ni priporočljiva uporaba vitamina B6 (piridoksina) za simptomatično ali sekundarno profilaktično zdravljenje sindroma roka-noga.
If you stop taking Ecansya 
Če ste prenehali jemati zdravilo Ecansya
- in combination with docetaxel (see section 5.1) for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. 
- v kombinaciji z docetakselom (glejte poglavje 5.1) za zdravljenje bolnikov z lokalno napredovalo ali metastatsko obliko raka dojk po neuspešni citotoksični kemoterapiji.
In embryotoxicity and teratogenicity studies in mice, dose-related increases in foetal resorption and teratogenicity were observed. 
V študijah o embriotoksičnosti in teratogenosti pri miših so opazili od odmerka odvisno povečanje odmrtja ploda in teratogenost.
5 mg/kg intravenous 30-90 mins 
5 mg/kg intravensko 30-90 min
The elimination half-life (t1/2 in hours) of capecitabine, 5'-DFCR, 5'-DFUR, 5-FU and FBAL were 0.85, 1.11, 0.66, 0.76 and 3.23 respectively. 
Razpolovne dobe izločanja (t1/2 v urah) kapecitabina, 5'-DFCR, 5'-DFUR, 5-FU in FBAL so bile 0,85; 1,11; 0,66; 0,76 in 3,23.
Cardiovascular toxicity (e.g. PR- and QT-interval prolongation) was detectable in cynomolgus monkeys after intravenous administration (100 mg/kg) but not after repeated oral dosing (1379 mg/m2/day). 
Toksično delovanje na srce in ožilje (podaljšanje intervalov PR in QT) so opazili pri opicah cynomolgus po intravenskem dajanju (100 mg/kg), po večkratnem peroralnem dajanju (1.379 mg/m2/dan) pa ne.
HR (97.5% CI) 
Razmerje ogroženosti (97,5 % CI)
In patients with unrecognised DPD deficiency treated with capecitabine as well as in those patients who test negative for specific DPYD variations, life-threatening toxicities manifesting as acute overdose may occur (see section 4.9). 
Pri bolnikih, pri katerih pomanjkanje DPD ni znano, kot tudi pri bolnikih z negativnim testom za specifične spremembe gena DPYD, ki jih zdravimo s kapecitabinom, se lahko pojavijo življenjsko ogrožujoče toksičnosti, ki se izrazijo kot akutno prekomerno odmerjanje (glejte poglavje 4.9).
The pooled analysis includes 3097 patients treated with capecitabine-containing regimens and 3074 patients treated with 5-FU-containing regimens. 
Skupna analiza je zajela 3.097 bolnikov, katerih zdravljenje je vključevalo kapecitabin, in 3.074 bolnikov, katerih zdravljenje je vključevalo 5-FU.
The XELIRI has been compared with 5-FU + irinotecan (FOLFIRI) in three randomised studies in patients with metastatic colorectal cancer. 
Shemo XELIRI so pri bolnikih z metastatskim kolorektalnim rakom primerjali s 5-FU + irinotekanom (FOLFIRI) v treh randomiziranih študijah.
Antacid: the effect of an aluminium hydroxide and magnesium hydroxide-containing antacid on the pharmacokinetics of capecitabine was investigated. 
Antacid: Proučevali so vpliv antacida, ki vsebuje aluminijev hidroksid in magnezijev hidroksid, na farmakokinetiko kapecitabina.
Also, you need to be particularly careful if you are taking any of the following: - gout medicines (allopurinol), - blood-thinning medicines (coumarin, warfarin), - medicines for seizures or tremors (phenytoin), - interferon alpha, - radiotherapy and certain medicines used to treat cancer (folinic acid, oxaliplatin, bevacizumab, 
Posebno previdni morate biti tudi pri uporabi: - zdravil proti protinu (alopurinola), - zdravil proti strjevanju krvi (kumarinov, varfarina), - zdravil za preprečevanje epileptičnih napadov ali tremorja (fenitoina), - interferona alfa, - radioterapije in nekaterih zdravil za zdravljenje raka (folinske kisline, oksaliplatina,
ADRs are added according to the highest incidence seen in any of the major combination trials. 
Neželeni učinki so dodani glede na največjo pogostnost, ki so jo opazili v katerem koli glavnem preskušanju s kombinacijo zdravil.
In vitro human plasma studies have determined that capecitabine, 5'-DFCR, 5'-DFUR and 5-FU are 54%, 10%, 62% and 10% protein bound, mainly to albumin. 
Študije in vitro na človeški plazmi so pokazale, da se na proteine (v glavnem na albumin) veže 54 % kapecitabina, 10 % 5'-DFCR, 62 % 5'-DFUR in 10 % 5-FU.
During a treatment cycle for those toxicities considered by the treating physician not to be related to capecitabine, capecitabine should be continued and the dose of the other medicinal product should be adjusted according to the appropriate Prescribing Information. 
Kadar se med ciklom zdravljenja pojavijo toksičnosti, za katere lečeči zdravnik meni, da niso povezane s kapecitabinom, je zdravljenje s kapecitabinom treba nadaljevati, odmerek drugega zdravila pa prilagoditi v skladu s primernim povzetkom glavnih značilnosti zdravila.
Children and adolescents Ecansya is not indicated in children and adolescents. 
Zdravilo Ecansya ni namenjeno otrokom in mladostnikom.
If these side effects continue, however, contact your doctor immediately. 
Če neželeni učinki ne izginejo, takoj pokličite zdravnika.
- metastatic colorectal cancer (see section 5.1). 
- za zdravljenje metastatske oblike kolorektalnega raka (glejte poglavje 5.1).
If the patient becomes pregnant while receiving capecitabine, the potential hazard to the foetus must be explained. 
Če bolnica med zdravljenjem s kapecitabinom zanosi, ji je treba razložiti možno tveganje za plod.
Parameter: Progression-free Survival EPP ITT Parameter: Overall Survival EPP ITT 
Parameter: Preživetje brez napredovanja bolezni EPP ITT Parameter: Celokupno preživetje EPP ITT
The overall objective response rates in the all-randomised population (investigator assessment) were 25.7% (capecitabine) vs. 16.7% (Mayo regimen); p <0.0002. 
Celokupen odgovor v randomiziranih skupinah (raziskovalčeva ocena) je bil 25,7 % (kapecitabin) v primerjavi s 16,7 % (shema Mayo); p < 0,0002.
If grade 2 or 3 hand-foot syndrome occurs, administration of capecitabine should be interrupted until the event resolves or decreases in intensity to grade 1. 
Če se pojavi sindrom 2. ali 3. stopnje, je treba jemanje kapecitabina prekiniti, dokler simptomi ne ponehajo oziroma se ne zmanjšajo na 1. stopnjo.
Caution must be exercised in patients with diabetes mellitus or electrolyte disturbances, as these may be aggravated during capecitabine treatment. 
Sladkorna bolezen ali elektrolitske motnje: Pri bolnikih s sladkorno boleznijo ali elektrolitskimi motnjami je potrebna previdnost, ker se njihovo stanje med zdravljenjem s kapecitabinom lahko poslabša.
Patients with certain heterozygous DPYD variants (including DPYD*2A, c.1679T>G, c.2846A>T and c.1236G>A/HapB3 variants) have been shown to have increased risk of severe toxicity when treated with capecitabine. 
Izkazalo se je, da imajo bolniki z določenimi heterozigotnimi različicami DPYD (vključno z različicami DPYD*2A, c.1679T>G, c.2846A>T in c.1236G>A/HapB3) pri zdravljenju s kapecitabinom večje tveganje za hudo toksičnost.
Capecitabine was not mutagenic in vitro to bacteria (Ames test) or mammalian cells (Chinese hamster V79/HPRT gene mutation assay). 
Kapecitabin in vitro pri bakterijah (Amesov test) ali celicah sesalcev (kitajski hrček V79/HPRT, metoda genske mutacije) ni bil mutagen.
The median duration of survival was 10.5 months (capecitabine + cisplatin) versus 9.3 months (5-FU + cisplatin). 
Mediana trajanja preživetja je bila 10,5 meseca (kapecitabin + cisplatin) v primerjavi z 9,3 meseca (5-FU + cisplatin).
Posology Recommended posology (see section 5.1): 
Odmerjanje Priporočeno odmerjanje (glejte poglavje 5.1):
Patients receiving concomitant capecitabine and oral coumarin-derivative anticoagulant therapy should have their anticoagulant response (INR or prothrombin time) monitored closely and the anticoagulant dose adjusted accordingly (see section 4.5). 
Bolnikom, ki sočasno prejemajo kapecitabin in peroralni kumarinski antikoagulant, je treba skrbno spremljati antikoagulantni odziv (INR ali protrombinski čas) ter ustrezno prilagajati odmerek antikoagulanta (glejte poglavje 4.5).
Currently, no comparative data are available on capecitabine monotherapy in colorectal cancer in comparison with first line combination regimens. 
Trenutno še nimamo podatkov o primerjavi samostojnega zdravljenja s kapecitabinom s kombiniranim zdravljenjem v okviru prvega zdravljenja.
In the case of colorectal tumours, 5-FU generation appears to be in large part localised in tumour stromal cells. 
Pri kolorektalnih tumorjih je generacija 5-FU močno lokalizirana v tumorskih stromalnih celicah.
Some of the ADRs are reactions commonly seen with the combination medicinal product (e.g. peripheral sensory neuropathy with docetaxel or oxaliplatin, hypertension seen with bevacizumab); however an exacerbation by capecitabine therapy cannot be excluded. 
Nekatere neželene učinke pogosto opazijo pri zdravljenju z zdravilom iz kombinacije (npr. periferno senzorično nevropatijo pri docetakselu ali oksaliplatinu, hipertenzijo pri bevacizumabu); vseeno pa njihovega poslabšanja pri zdravljenju s kapecitabinom ne moremo izključiti.
XELOX or XELOX+ Bevacizumab 
shema XELOX + bevacizumab
Radiotherapy: the MTD of capecitabine alone using the intermittent regimen is 3000 mg/m2 per day, whereas, when combined with radiotherapy for rectal cancer, the MTD of capecitabine is 2000 mg/m per day using either a continuous schedule or given daily Monday through Friday during a 6-week course of radiotherapy. 
Radioterapija: Največji prenosljivi odmerek kapecitabina samega pri intermitentnem dajanju je 3.000 mg/m2 na dan, v kombinaciji z radioterapijo za rak danke pa je največji prenosljivi odmerek kapecitabina 2.000 mg/m2 na dan z uporabo neprekinjene sheme ali dnevnim dajanjem od ponedeljka do petka med 6-tedensko radioterapijo.
Thymidine phosphorylase activity was measured and found to be 4 times greater in primary colorectal tumour than in adjacent normal tissue. 
Aktivnost timidin fosforilaze je štirikrat večja v primarnih kolorektalnih tumorjih kot v sosednjih zdravih tkivih.
Aluminium/aluminium or PVC/PVdC/aluminium blister containing 10 film-coated tablets. 
Al/Al ali PVC/PVdC/Al pretisni omoti vsebujejo 10 filmsko obloženih tablet.
7.5 mg/kg intravenous 30-90 mins 
7,5 mg/kg intravensko 30-90 min